ATE435303T1 - Verfahren und zusammensetzungen in verbindung mit gen-silencing - Google Patents

Verfahren und zusammensetzungen in verbindung mit gen-silencing

Info

Publication number
ATE435303T1
ATE435303T1 AT03784781T AT03784781T ATE435303T1 AT E435303 T1 ATE435303 T1 AT E435303T1 AT 03784781 T AT03784781 T AT 03784781T AT 03784781 T AT03784781 T AT 03784781T AT E435303 T1 ATE435303 T1 AT E435303T1
Authority
AT
Austria
Prior art keywords
stranded rna
double
fragments
gene silencing
sequences
Prior art date
Application number
AT03784781T
Other languages
English (en)
Inventor
George Tzertzinis
George Feehery
Corinna Tuckey
Christopher Noren
Larry Mcreynolds
Original Assignee
New England Biolabs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Biolabs Inc filed Critical New England Biolabs Inc
Application granted granted Critical
Publication of ATE435303T1 publication Critical patent/ATE435303T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/26Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
    • C12Y301/26003Ribonuclease III (3.1.26.3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/30Production chemically synthesised
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/30Production chemically synthesised
    • C12N2330/31Libraries, arrays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Silicon Polymers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03784781T 2002-08-12 2003-07-18 Verfahren und zusammensetzungen in verbindung mit gen-silencing ATE435303T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40276902P 2002-08-12 2002-08-12
US40754302P 2002-08-30 2002-08-30
US46754103P 2003-05-02 2003-05-02
PCT/US2003/022540 WO2004015062A2 (en) 2002-08-12 2003-07-18 Methods and compositions relating to gene silencing

Publications (1)

Publication Number Publication Date
ATE435303T1 true ATE435303T1 (de) 2009-07-15

Family

ID=31721504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03784781T ATE435303T1 (de) 2002-08-12 2003-07-18 Verfahren und zusammensetzungen in verbindung mit gen-silencing

Country Status (8)

Country Link
US (2) US7700758B2 (de)
EP (1) EP1552018B1 (de)
JP (1) JP4339852B2 (de)
CN (1) CN1685063B (de)
AT (1) ATE435303T1 (de)
AU (1) AU2003256615A1 (de)
DE (1) DE60328214D1 (de)
WO (1) WO2004015062A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2213737B1 (de) 2002-02-01 2012-11-07 Life Technologies Corporation Doppelsträngige Oligonukleotide
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
CA2486658C (en) * 2002-05-31 2014-07-29 The Regents Of The University Of California Method for efficient rna interference in mammalian cells
US20100075423A1 (en) * 2002-06-12 2010-03-25 Life Technologies Corporation Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20050059019A1 (en) * 2003-09-11 2005-03-17 Sven Bulow Gene-related RNAi transfection method
WO2005026322A2 (en) * 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
EP1706511A4 (de) * 2004-01-23 2010-04-07 New England Biolabs Inc Zusammensetzungen und verfahren zur erzeugung kurzer doppelsträngiger rna unter verwendung von mutierter rnase iii
WO2005095647A1 (ja) * 2004-03-31 2005-10-13 Takara Bio Inc. siRNAのスクリーニング方法
BRPI0510996A (pt) * 2004-05-19 2007-12-04 Wyeth Corp métodos para melhorar um sintoma de um distúrbio atópico, e para tratar ou prevenir um distúrbio atópico em um paciente, métodos para modular a produção de igg e ige em uma célula, e nìveis relativos de ige e igg, composição farmacêutica, recipiente, métodos para avaliar um paciente tendo ou suspeito de ter um distúrbio atópico, e para avaliar um paciente quanto ao risco de um distúrbio atópico
WO2006000410A2 (en) * 2004-06-23 2006-01-05 Bayer Bioscience N.V. Method for identifying nucleic capable of modulating a gene in a biological system
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
CN102989012B (zh) 2005-03-31 2015-05-13 通用医疗公司 监测和调制hgf/hgfr活性
CN103638522A (zh) 2006-01-18 2014-03-19 通用医疗公司 增强淋巴功能的方法
CN101494978A (zh) 2006-05-25 2009-07-29 比奥根艾迪克Ma公司 治疗中风的方法
SI2056845T1 (en) 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES
BRPI0721236A2 (pt) * 2007-01-29 2015-09-08 Wyeth Corp complexo purificado; célula hospedeira recombinante; método para identificar um composto teste que aumenta a formação de um complexo que inclui o composto teste; método de aumentar a formação de um complexo que inclui um ligante de imunofilina; método de diminuir a atividade do canal de cálcio da abertura dependente da tensão da membrana, e/ou atividade fkbp52, em uma célula; método de estimular o crescimento de neurite e/ou sobrevivência de uma célula neuronal; método de tratar um distúbio associado com disfunção de canal de cálcio tipo l; método de estimular o crescimento de neurite de uma célula neuronal; uso de um ligante de imunofilina; uso de um ligante de imunofilina em combinação com um antagonista do canal de cálcio tipo l; ligante de imunofilina; e composição.
EP2137655B1 (de) 2007-04-16 2012-07-11 Momenta Pharmaceuticals, Inc. Definierte glycoproteinprodukte und entsprechende verfahren
WO2009070465A1 (en) * 2007-11-29 2009-06-04 New England Biolabs, Inc. Selective purification of small rnas from mixtures
EP2297323A1 (de) 2008-05-21 2011-03-23 Hartmann, Gunther 5 -triphosphat-oligonukleotid mit stumpfem ende und verwendugen davon
EP2982695B1 (de) 2008-07-09 2019-04-03 Biogen MA Inc. Zusammensetzungen mit antikörpern gegen lingo oder fragmenten davon
AU2009313203B2 (en) 2008-11-10 2015-08-27 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
WO2013028817A1 (en) 2011-08-23 2013-02-28 Foundation Medicine , Inc. Novel kif5b-ret fusion molecules and uses thereof
KR102142161B1 (ko) 2012-05-14 2020-08-06 바이오젠 엠에이 인코포레이티드 운동 뉴런 관련 병태 치료용 lingo-2 길항제
AU2013296237B2 (en) 2012-08-03 2019-05-16 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
US20150238602A1 (en) 2012-10-09 2015-08-27 Biogen Idec Ma Inc. Combination therapies and uses for treatment of demyelinating disorders
AU2013337277B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel NTRK1 fusion molecules and uses thereof
EP2945652B1 (de) 2013-01-18 2021-07-07 Foundation Medicine, Inc. Verfahren zur behandlung cholangiokarzinom
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
EP2971161B1 (de) 2013-03-15 2018-12-26 ModernaTX, Inc. Nukleinsäurereinigung
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US20160051673A1 (en) 2013-03-29 2016-02-25 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
SI3019619T1 (sl) 2013-07-11 2021-12-31 Modernatx, Inc. Sestave, ki zajemajo sintetične polinukleotide, ki kodirajo proteine, pozvezane s crispr, in sintetične sgrna, ter metode uporabe
AU2014290044B2 (en) 2013-07-17 2020-10-29 Foundation Medicine, Inc. Methods of treating urothelial carcinomas
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
EP3169335B8 (de) 2014-07-16 2019-10-09 ModernaTX, Inc. Kreisförmige polynukleotide
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. Lingo‐1拮抗薬及び脱髄障害の治療のための使用
EP3349773A4 (de) 2015-09-14 2019-05-01 Cincinnati Children's Hospital Medical Center Verfahren und zusammensetzungen zur behandlung der gaucher-krankheit durch modulation des c5a-rezeptors
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
WO2017151517A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
JP7149257B2 (ja) 2016-07-13 2022-10-06 バイオジェン・エムエイ・インコーポレイテッド Lingo-1アンタゴニストの投与計画及び脱髄障害の処置のための使用
US20210261897A1 (en) * 2018-06-28 2021-08-26 Curevac Ag Bioreactor for rna in vitro transcription
WO2020058759A1 (en) 2018-09-17 2020-03-26 Kyoto University Administration of an anti-c5 agent for treatment of hepatic injury or failure
CN111073885A (zh) * 2019-12-31 2020-04-28 江苏耀海生物制药有限公司 一种应用于双链dna片段的纯化方法
CN112626152A (zh) * 2020-12-18 2021-04-09 深圳大学 siRNA的制备方法
CN113621686A (zh) * 2021-08-11 2021-11-09 海南微氪生物科技股份有限公司 一种适用于多种病原微生物的检测方法
WO2024045192A1 (en) * 2022-09-02 2024-03-07 Xiaomo Biotech Limited Inclusion body mediated method for double-stranded rna producing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CN101818145A (zh) 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
EP1147204A1 (de) 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Zusammensetzung und verfahren zur in vivo und in vitro abschwächung der genexpression mittels dobbelsträngigem rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
KR20020097198A (ko) 2000-03-17 2002-12-31 베니텍 오스트레일리아 리미티드 유전자 사일런싱
DK2796553T3 (da) 2000-03-30 2019-09-30 Whitehead Inst Biomedical Res Rna-sekvensspecifikke formidlere af rna-interferens
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
AU2002258477A1 (en) 2001-03-08 2002-09-24 Advanced Cell Technology, Inc. Use of rna interference for the creation of lineage specific es and other undifferentiated cells and production of differentiated cells in vitro by co-culture
US7101995B2 (en) 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
CA2486658C (en) * 2002-05-31 2014-07-29 The Regents Of The University Of California Method for efficient rna interference in mammalian cells

Also Published As

Publication number Publication date
EP1552018A4 (de) 2007-11-21
EP1552018A2 (de) 2005-07-13
AU2003256615A8 (en) 2004-02-25
WO2004015062A3 (en) 2005-02-24
DE60328214D1 (de) 2009-08-13
WO2004015062A2 (en) 2004-02-19
CN1685063A (zh) 2005-10-19
US20080206835A1 (en) 2008-08-28
CN1685063B (zh) 2011-12-21
US20040038278A1 (en) 2004-02-26
JP4339852B2 (ja) 2009-10-07
AU2003256615A1 (en) 2004-02-25
EP1552018B1 (de) 2009-07-01
JP2005535356A (ja) 2005-11-24
US7700758B2 (en) 2010-04-20

Similar Documents

Publication Publication Date Title
ATE435303T1 (de) Verfahren und zusammensetzungen in verbindung mit gen-silencing
Van Dijk et al. Library preparation methods for next-generation sequencing: tone down the bias
Bernt et al. Genetic aspects of mitochondrial genome evolution
DE60324188D1 (de) Verfahren zur verwendung von riboprimern zur strangverdrängungsreplikation von zielsequenzen
ATE469983T1 (de) Rolling-circle rna-amplifikation
WO2004058940A3 (en) Sirna-mediated gene silencing
ATE542918T1 (de) Verfahren zur quantifizierung von mikro-rnas und kleinen interferenz-rnas
ATE483032T1 (de) Verfahren zur herstellung von oligonukleotiden
AR039717A1 (es) Construcciones de arn de intrones cadena doble y usos de las mismas
DE60331321D1 (de) Verfahren zur wirksamen rna-interferenz in säugerzellen
Li et al. Identification and characterization of microRNAs in the spleen of common carp immune organ
Ohadi et al. Core promoter short tandem repeats as evolutionary switch codes for primate speciation
TNSN08252A1 (en) Sirna anti myosine va et depigmentation de la peau
DE602005022443D1 (de) Schnelle synthese von oligonukleotiden
MX2007004686A (es) Moleculas de arn de multidominio que comprenden al menos un aptamero para suministrar arn de doble hebra a organismos nocivos.
JP2021520221A (ja) 新規小分子活性化rna
WO2006045591A3 (en) Method and constructs for delivering double stranded rna to pest organisms
BR0309766A (pt) Promotores usp semente especìficos para expressar genes em vegetais
PE20212248A1 (es) Molecula oligomerica de acido nucleico y uso de esta
WO2003104470A3 (en) LET US RETURN FOR GENE TARGETING
WO2005042705A3 (en) Short interfering rna and micro-rna compounds and methods of designing, making and using the same
MXPA02003422A (es) Alteracion de la expresion de genes con adnss producido in vivo.
WO2009008645A3 (en) Linear double-stranded rna molecule interfering with different target genes
WO2004094616A3 (en) Silencing transcription by methylation
ATE491035T1 (de) Verfahren zur abtrennung selektionierbarer markergensequenzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties